Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZR-MD-001 enhancement study for Meibomian Gland Dysfunction
NCT04314362Phase 3Completed
- Sponsor
- Azura Ophthalmics
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of selenium sulfide ophthalmic ointment in meibomian gland dysfunction (MGD) (3 arms), sponsored by Azura Ophthalmics. Primary endpoint: Change From Baseline to Month 3 in Meibomian Gland Secretion Score (MGS). Started Jul 2020; status: completed.
02
Drugs
selenium sulfide ophthalmic ointment
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT04314362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314362.